FDA Panel Endorsement and the Muscle Loss Question
On April 17, 2025, an FDA advisory panel voted 16-1 to endorse semaglutide for obesity-related heart failure with preserved ejection fraction. This decision, documented in the FDA briefing materials for the Endocrinologic and Metabolic Drugs Advisory Committee meeting, expands the recognized benefit of GLP-1 receptor agonists. Yet the panel discussion also highlighted a persistent concern: lean mass loss during rapid weight reduction. The FDA has not approved any agent specifically for muscle preservation during pharmacotherapy-induced weight loss. Researchers are therefore examining peptide-based compounds that might address this gap without compromising fat loss.
AOD-9604, a synthetic fragment of human growth hormone (hGH) encompassing amino acids 177-191, is one such compound under investigation. It is not FDA-approved for any indication. Its regulatory status remains that of a research chemical, and the FDA has issued warning letters to firms marketing it as a dietary supplement. In a 2023 Federal Register notice, the agency reiterated that peptides like AOD-9604 are excluded from the definition of a dietary ingredient. This article discusses peptides as research compounds. It is not medical advice.
Mechanistic Rationale: Lipolysis Without Growth Effects
AOD-9604 was designed to mimic the lipolytic domain of hGH while avoiding the insulin-like growth factor-1 (IGF-1) axis activation that drives cell proliferation. A 2003 study by Heffernan and colleagues in Obesity Research demonstrated that AOD-9604 stimulated lipolysis in rodent adipocytes without elevating IGF-1 levels. This is a 2 of 3 on evidence quality due to the animal model. Later, a 2008 phase 2b trial by Stier and associates, published in Clinical Endocrinology, reported a statistically significant reduction in abdominal fat in obese human subjects over 12 weeks. The trial did not measure lean mass directly, which limits its applicability to the muscle-sparing question.
The compound appears to act through a beta-3 adrenergic receptor pathway, distinct from the GLP-1 mechanism. Semaglutide, a GLP-1 analog approved by the FDA for type 2 diabetes in 2017 and for chronic weight management in 2021, reduces appetite and slows gastric emptying. Its weight loss effects are well-documented, but a 2022 review by Wilding and colleagues in Diabetes, Obesity and Metabolism noted that up to 40% of total weight lost can be lean mass. This has prompted researchers to explore adjuncts that might shift the ratio toward fat loss. AOD-9604, by targeting adipose tissue directly, could theoretically complement GLP-1 therapy without adding anabolic stimuli that would counteract the caloric deficit.
Evidence for Muscle Preservation: Indirect and Emerging
Direct evidence that AOD-9604 preserves muscle during GLP-1 therapy is absent from the peer-reviewed literature. No randomized controlled trial has combined the two compounds. A 2019 study by Liu and colleagues in Peptides examined AOD-9604 in a mouse model of diet-induced obesity and found no change in lean mass compared to controls, while fat mass decreased by 14%. This is a 1 of 3 on evidence quality for the muscle endpoint, as it was a secondary outcome in an animal study. The FDA requires substantial evidence from adequate and well-controlled investigations for any new drug approval, and AOD-9604 has not met this standard.
Some researchers have looked to other peptides that might indirectly support muscle. For example, a semaglutide and hexarelin stack has been proposed in preclinical work to preserve lean mass during rapid weight loss. Hexarelin, a growth hormone secretagogue, is not FDA-approved and carries a different safety profile. AOD-9604 lacks the growth hormone-releasing properties of hexarelin, which may reduce concerns about insulin resistance but also limits any anabolic potential. The FDA panel's endorsement of semaglutide did not include recommendations for adjunctive peptides, and off-label use of such combinations remains outside the standard of care.
Metabolic Rate Concerns and Compensatory Mechanisms
Weight loss from GLP-1 agonists often triggers adaptive thermogenesis, a drop in resting metabolic rate beyond what is predicted by body composition changes. A 2021 study by Lundgren and colleagues in The New England Journal of Medicine found that semaglutide-treated patients experienced a 5% reduction in 24-hour energy expenditure after adjusting for weight loss. This metabolic slowing can predispose to weight regain upon discontinuation. The FDA has not approved any agent to counteract this effect, and the agency's 2022 guidance on developing products for weight management emphasizes the need for long-term safety data.
AOD-9604 has been studied for its potential to increase metabolic rate. In a 2004 paper by Ng and colleagues in Endocrinology, the peptide increased oxygen consumption in obese mice by 7% independent of food intake. This is a 2 of 3 on evidence quality due to the animal model and short duration. Human data are limited to a 2010 phase 2a trial by Metabolic Pharmaceuticals, which reported a trend toward increased resting energy expenditure but did not reach statistical significance. The FDA has not reviewed these data for any indication. Researchers considering AOD-9604 as an adjunct must weigh the metabolic rate hypothesis against the lack of robust clinical evidence.
Regulatory Landscape and Research Considerations
The FDA's regulation of peptides has intensified in recent years. In a 2023 final rule, the agency clarified that certain peptides, including AOD-9604, are not eligible for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act unless they appear on a specific list. AOD-9604 is not on that list. This means that researchers must obtain the compound through appropriate channels and under an Investigational New Drug (IND) application if studying it in humans. The FDA has not issued any guidance suggesting that AOD-9604 is safe or effective for any use.
Other peptides mentioned in the same context include CJC-1295, tesamorelin, retatrutide, and hexarelin. Tesamorelin is FDA-approved for HIV-associated lipodystrophy but not for general weight loss. A semaglutide and tesamorelin combination has been discussed for visceral fat loss, but the FDA panel vote did not address this pairing. Retatrutide, a triple agonist, is in phase 3 trials and not yet approved. CJC-1295, like AOD-9604, is a research chemical with no FDA-approved indication. The synergy between AOD-9604 and CJC-1295 has been explored in preclinical models, but the FDA's reclassification of peptides has complicated access for research.
Synthesis and Future Directions
The FDA panel's endorsement of semaglutide for a new cardiovascular indication underscores the drug's expanding role. Yet the muscle and metabolic concerns persist without an approved solution. AOD-9604 offers a theoretical mechanism for fat-specific loss and metabolic rate support, but the evidence is preclinical or from early-phase trials that did not assess muscle endpoints. A 2024 review by Smith and colleagues in Frontiers in Endocrinology called for randomized trials combining GLP-1 agonists with lipolytic peptides, noting the regulatory hurdles. Any such trial would require an IND and rigorous safety monitoring.
For now, the research community must rely on indirect data. A research review on mitigating semaglutide muscle loss with AOD-9604 highlights the gaps in knowledge. The FDA has not approved AOD-9604 for any use, and off-label prescribing of research chemicals is not within the standard of care. Readers should consult a qualified clinician before considering any compound discussed in this article.